The research, led by Jan-Michel Heger of University Hospital Cologne together with colleagues from centers across Germany and Austria, set out to validate which variables are clinically relevant prognostic factors and which act as treatment-effect modifiers in DLBCL. The distinction is technically crucial. A prognostic factor predicts how patients fare overall regardless of which therapy they receive, such as advanced age or high tumor burden. A treatment-effect modifier, by contrast, changes how well a specific therapy works, meaning the treatment’s benefit itself differs depending on the patient’s status. Confusing the two can distort indirect treatment comparisons, the family of statistical methods, including matching-adjusted and simulated treatment comparisons, that health technology assessment bodies increasingly rely on when randomized evidence is absent. If an effect modifier is left unadjusted, the comparison may attribute differences in outcome to the drug when they actually stem from the patient mix.

To build the variable list, the team first drew on a prior systematic literature review of prognostic factors for efficacy and safety outcomes of CAR-T therapy in DLBCL, then refined the candidates through clinical review. Six experienced hematologists and oncologists from Germany and Austria, institutions spanning Cologne, Berlin, Essen, and Vienna, then participated in a structured, two-round expert elicitation process modeled on consensus methodologies such as the Delphi approach. Each expert rated the importance of every candidate variable as a prognostic factor, a treatment-effect modifier, or both, using a three-point Likert scale. Variables that crossed predefined consensus thresholds were assigned to relevance tiers and then mapped to specific clinical endpoints: progression-free survival, overall survival, response outcomes, and CAR-T-related toxicities such as cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome, the two signature adverse events of this therapeutic class.

The findings on prognostic factors were remarkably coherent. Thirteen variables reached the top relevance tier: Eastern Cooperative Oncology Group performance status, age, disease histology, the International Prognostic Index, disease stage, elevated lactate dehydrogenase, bulky disease, extranodal involvement, tumor burden, primary refractory disease, number of relapses, time to relapse, and the number of prior lines of therapy. Six of these achieved unanimous agreement among all panelists as prognostic factors for survival outcomes: ECOG performance status, the IPI, disease histology, disease stage, elevated LDH, and primary refractory disease. These are, for the most part, the venerable workhorses of lymphoma prognostication. The IPI, developed in the early 1990s, combines age, performance status, stage, LDH, and extranodal sites into a single risk score, and its components dominated the panel’s top tier, suggesting that decades of clinical experience have produced a stable, shared understanding of what drives outcomes in aggressive B-cell malignancy.

The logic behind each variable is biologically plausible. ECOG performance status captures a patient’s functional fitness, which influences both tolerance of intensive lymphodepleting chemotherapy before CAR-T infusion and the ability to survive complications. Elevated LDH signals high tumor turnover and burden. Primary refractory disease, meaning lymphoma that never responded to initial therapy, and short time to relapse both mark biologically aggressive, treatment-resistant clones. Number of prior therapy lines reflects cumulative exposure to cytotoxic regimens and often correlates with diminishing responsiveness. Bulky disease and high tumor burden strain not only efficacy but also safety, a point the panel emphasized: tumor burden-related variables were judged important for both efficacy endpoints and toxicity outcomes, including the risk of cytokine release syndrome, in which engineered T cells trigger a systemic inflammatory cascade, and neurotoxicity, which can range from mild confusion to life-threatening cerebral edema.

Where consensus weakened was precisely where the science is least mature: treatment-effect modifiers. Compared with the strong agreement on prognostic factors, substantially lower agreement emerged for effect modifiers, particularly for response-based outcomes such as complete response and overall response rates. Only a handful of variables reached the top tier as effect modifiers: primary refractory disease, time to first relapse, best response to prior therapy, bridging therapy, CAR-T product type, and CAR-T-related response characteristics. Bridging therapy, the treatment given between leukapheresis, when a patient’s T cells are harvested for engineering, and infusion of the final CAR-T product, was the sole modifier to achieve unanimous agreement for complete and overall response rates. That makes intuitive sense: bridging therapy both controls disease during the manufacturing window and may itself select for or against certain patient profiles, entangling its effect with the therapy being evaluated.

The asymmetry between prognostic factors and effect modifiers is not a failure of the panel but a reflection of the evidence base. Identifying a prognostic factor requires only observing that outcomes vary with a characteristic; identifying an effect modifier requires evidence that the magnitude of a treatment’s benefit differs across levels of that characteristic, which demands comparative data that are often simply unavailable. Recent real-world analyses comparing tisagenlecleucel and axicabtagene ciloleucel, the two most widely used CD19-directed CAR-T products in DLBCL, have begun to probe such interactions, but the literature remains thin and heterogeneous. The panel’s hesitancy, in other words, encodes genuine scientific uncertainty rather than disagreement about method. For analysts constructing indirect comparisons, this means adjustment strategies for effect modification must be justified case by case, with sensitivity analyses exploring how conclusions change under different assumptions.

The study’s methodology also carries lessons for the broader field of comparative effectiveness research. Structured expert elicitation has become an accepted tool when empirical data cannot settle a question, and the two-round design with predefined consensus thresholds guards against the dominance of a single loud voice. The approach mirrors frameworks developed by health technology assessment bodies, including the German Institute for Quality and Efficiency in Health Care, which has promoted systematic confounder identification in indirect comparisons. By allocating variables to specific endpoints rather than treating confounding as a generic problem, the panel acknowledged a technical subtlety: a variable may be essential to adjust for when comparing progression-free survival but irrelevant for response rates, and a variable that predicts toxicity, such as tumor burden’s link to cytokine release syndrome, may need separate consideration in safety analyses.

There are caveats worth noting. The panel comprised six clinicians from two neighboring countries with broadly similar treatment landscapes, and their judgments, however experienced, are ultimately structured opinion rather than empirical proof. The study was funded by Miltenyi Biomedicine, a manufacturer of CAR-T technology, with several authors employed by the company or a contract research organization, although the funder reported no role in study design, data collection, or interpretation. Participants were compensated, and the elicitation captured physician judgment rather than patient-level data. These limitations do not undermine the central contribution, but they mean the resulting variable list should be treated as a validated starting framework, to be updated as real-world registries and comparative studies accumulate.

For patients with relapsed or refractory DLBCL, the practical stakes are considerable. CAR-T therapy has transformed outcomes for a population that once had few options, but the therapy is expensive, logistically demanding, and carries real risks, so payers and clinicians need trustworthy evidence about which product or sequence works best for whom. Indirect comparisons are often the only bridge across the gaps in randomized evidence, and this study supplies the engineering specifications for that bridge: a consensus-backed set of prognostic factors that must be balanced, a shorter and more tentative list of effect modifiers demanding caution, and an explicit mapping of variables to endpoints. The next step, the authors and the field suggest, is to test these expert-identified variables empirically in large, multinational real-world datasets, turning structured clinical intuition into statistically verified adjustment models that can withstand regulatory scrutiny.

Subject of Research: Confounder and effect-modifier identification for indirect treatment comparisons of CAR-T therapy in relapsed or refractory diffuse large B-cell lymphoma

Article Title: Confounder Identification in Diffuse Large B-Cell Lymphoma: Findings from an Expert Panel of German and Austrian Hematologists

Article References: Heger, J.-M., Gödel, P., Habringer, S., Jäger, U., Kutsch, N., von Tresckow, B., Zhang, R., Rungaldier, S., Oddsdottir, J., Zacharioudaki, M., & Mahlich, J. (2026). Confounder Identification in Diffuse Large B-Cell Lymphoma: Findings from an Expert Panel of German and Austrian Hematologists. Advances in Therapy. https://doi.org/10.1007/s12325-026-03820-z

Image Credits: AI Generated

DOI: 10.1007/s12325-026-03820-z

Keywords: diffuse large B-cell lymphoma, CAR-T therapy, confounders, prognostic factors, treatment-effect modifiers, indirect treatment comparisons, expert consensus, bridging therapy, cytokine release syndrome, International Prognostic Index, health technology assessment, hematology

The biological logic behind the combination is what sets it apart from many single-cell approaches. Solid tumors are not uniform targets; they are heterogeneous collections of malignant cells that deploy overlapping but distinct strategies to evade immune attack. Natural killer cells belong to the innate immune system and can recognize and destroy stressed or abnormal cells without needing to identify a specific tumor antigen, making them valuable against cancer cells that have downregulated the surface molecules T cells typically rely on. T lymphocytes, by contrast, mediate adaptive immunity: when primed against tumor antigens, they can mount targeted, antigen-specific killing and generate immunological memory. By infusing both cell types together, the investigators aimed to attack the tumor through complementary mechanisms, reducing the likelihood that an immune-escape variant could slip through unscathed.

The trial design reflected its early-phase purpose. This was a single-arm study, meaning there was no placebo or control group, and all nine enrolled patients received the active therapy. Each participant had a recurrent or progressive solid tumor and had already undergone between one and three prior lines of systemic treatment, placing them squarely in the population where standard options have been exhausted. SDH-Combi was manufactured from each patient’s own cells—an autologous approach that avoids the rejection risks associated with donor material—and was administered as an infusion once every two weeks, for up to eight infusions in total. The primary endpoint was safety and tolerability, while secondary endpoints included objective response rate, disease control rate, progression-free survival, and overall survival, with tumor measurements assessed according to the widely used RECIST v1.1 criteria.

On the safety front, the results were strikingly clean for a cell therapy. Among the nine treated patients, no grade 3 or higher treatment-related adverse event occurred, a finding the investigators report with a 95 percent confidence interval of 0.0 to 33.6 percent. No patient discontinued treatment because of toxicity, no cases of cytokine release syndrome were observed, and there were no anaphylactic reactions or treatment-related serious adverse events. Cytokine release syndrome—a potentially dangerous inflammatory cascade that has complicated other cellular immunotherapies, most famously CAR T cell treatments—was a particular concern the trial was designed to monitor, and its complete absence is a notable point in the therapy’s favor.

Tolerability metrics reinforced the safety picture. Six of the nine patients, or 66.7 percent, completed all eight planned infusions, and 64 of the 72 planned infusions across the study—88.9 percent—were actually administered, indicating that the treatment schedule was practical for most participants. The single serious adverse event in the trial was a grade 4 anemia in one patient, whose hemoglobin fell to a nadir of 4.5 grams per deciliter, but the investigators judged this event unlikely to be related to the study therapy. All other adverse events were grades 1 or 2, the mildest categories on the standard CTCAE v5.0 grading scale used to classify treatment-emergent events.

The preliminary efficacy signals, while modest, were not negligible. In the full analysis set of nine patients, the disease control rate—encompassing complete responses, partial responses, and stable disease—reached 66.7 percent, suggesting that for a majority of these heavily pretreated patients, the therapy was associated with at least a halt in tumor progression. The objective response rate, which counts only measurable tumor shrinkage, was 11.1 percent, corresponding to a single patient among the nine. Median overall survival had not been reached at the time of the safety assessment, though five of the nine patients had died by the follow-up date of 14 January 2026. The authors are appropriately measured about these numbers, noting that formal statistical inference is limited by the small, single-arm sample size and the absence of a comparator group.

One of the more intriguing aspects of the study is its attention to quality of life, an exploratory endpoint measured with the validated EORTC QLQ-C30 questionnaire. Patients reported improvements that crossed the threshold for a minimal clinically important difference—defined as a change of at least 10 points—in five of the six functional domains assessed: global health status and quality of life, physical functioning, role functioning, emotional functioning, and social functioning. All nine symptom domains also showed changes meeting or approaching that threshold, with constipation showing a marginal improvement of 11.1 points, while cognitive functioning did not reach the clinically important threshold. For a population of patients with advanced, recurrent cancer, subjective improvements in daily functioning and well-being carry real weight, even in an uncontrolled setting where placebo effects and natural fluctuation cannot be excluded.

The trial was conducted under ethical approval from the Institutional Review Board of the Ministry of Health of Mongolia, with clinical sites including hospitals in Ulaanbaatar, and was funded by Seoul Songdo Hospital in South Korea, where the cell processing facility manufactured the autologous products. The collaboration highlights how cellular immunotherapy research is expanding geographically, and the authors acknowledge the substantial manufacturing effort required to produce patient-specific cell products on a clinical schedule. Autologous therapies of this kind demand that a patient’s own immune cells be collected, processed, expanded, and quality-controlled before being reinfused—a logistical and technical undertaking that shapes which patients can be treated and how quickly.

The authors conclude that SDH-Combi was feasible and well tolerated, with preliminary signals of disease stabilization and quality of life improvement in previously treated patients, findings they say support further clinical evaluation of this biologically rational combination cellular immunotherapy. That framing is the appropriate one for a phase 1 study: the trial was never designed to prove efficacy, only to establish that the approach can be delivered safely and consistently. What it has demonstrated is that combining autologous natural killer cells with tumor-primed T lymphocytes can be done without the severe toxicities that have shadowed other cell therapies, and that the treatment can be administered on a demanding every-two-week schedule with most patients completing the full course.

The road ahead will require larger, controlled trials to determine whether the disease control signals translate into meaningful extensions of survival, and which tumor types benefit most. The field of combination cellular immunotherapy is betting on a simple premise: that cancers are too adaptable to be defeated by any single immune cell type, and that deploying innate and adaptive immunity together closes the escape routes tumors rely on. With no grade 3 or higher treatment-related events, nearly 90 percent of planned infusions delivered, and a majority of patients experiencing disease control, this first-in-human evaluation gives that premise its earliest real-world test—and a reason for the field to keep watching.

Subject of Research: Phase 1 trial of autologous NK cell and T lymphocyte combination immunotherapy for recurrent solid tumors

Article Title: Phase 1 clinical trial evaluating the safety and preliminary efficacy of autologous NK cells combined with T lymphocytes in patients with recurrent solid tumors

Article References: Kim, K.-J., Lee, N., Che, D. N., Lee, H.-J., Lee, H. N., Tungalag, S., Batsukh, K., Nyamdavaa, T., Sohn, S.-K., & Lee, J. K. (2026). Phase 1 clinical trial evaluating the safety and preliminary efficacy of autologous NK cells combined with T lymphocytes in patients with recurrent solid tumors. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-026-04532-7

Image Credits: AI Generated

DOI: 10.1007/s00262-026-04532-7

Keywords: NK cells, T lymphocytes, cellular immunotherapy, solid tumors, phase 1 trial, autologous therapy, cancer immunotherapy, RECIST, quality of life, cytokine release syndrome, disease control, immune escape

The study collected clinical reports of nivolumab-induced cytokine release syndrome published before March 31, 2026, extracting clinical data for retrospective analysis. Thirty-five patients were included, spanning an extraordinarily wide age range from 3 to 86 years, with a median age of 55. That breadth alone carries a message for oncologists: the complication is not confined to any single tumor type, age group or treatment setting. It can emerge in children with refractory Hodgkin lymphoma and in elderly patients with solid tumors alike, wherever nivolumab is deployed to release the brakes on T-cell immunity.

Perhaps the most clinically consequential finding concerns timing. The median time from the start of nivolumab to the appearance of cytokine release syndrome was 54.5 days, with cases reported as early as 0.2 days and as late as 391 days after initiation. The median number of infusion cycles before onset was three, but the range stretched from one to seventeen. This late and highly variable onset distinguishes checkpoint inhibitor-associated cytokine release syndrome from the fulminant, early-onset syndrome seen after CAR T-cell infusion, where fever and hypotension typically erupt within days of cell transfer. A patient who develops fever and falling blood pressure months into nivolumab therapy may not immediately suggest a cytokine storm to the treating team, and the authors argue that the possibility of CRS should be explicitly considered throughout the entire course of administration, not just in the first weeks.

The clinical signature the researchers documented is dominated by fever, which affected 85.7 percent of patients. Hypotension followed in 57.1 percent, tachycardia in 42.9 percent, and fatigue, rash and impaired consciousness each appeared in 25.7 percent of cases. This constellation mirrors the physiology of uncontrolled immune activation: activated T cells and macrophages flood the circulation with inflammatory mediators, producing capillary leak, vasodilation and hemodynamic instability. Neurological involvement in the form of impaired consciousness underscores that the brain is not spared when cytokine levels climb, a feature also recognized in severe CAR T-cell-associated toxicity. In practical terms, a patient on nivolumab who presents with unexplained fever plus hypotension or altered mental status should raise immediate suspicion of CRS, even if the last infusion was months earlier.

Laboratory findings reinforce the inflammatory diagnosis. The reviewed cases commonly revealed liver injury, renal injury, elevated C-reactive protein, elevated ferritin and elevated interleukin-6. Each of these markers has a mechanistic rationale. Interleukin-6 is a central driver of the syndrome, amplifying the inflammatory cascade and contributing to vascular permeability. Ferritin, an acute-phase reactant produced abundantly by activated macrophages, has been proposed in prior literature as a diagnostic and prognostic marker for immune-related adverse events. C-reactive protein rises rapidly under interleukin-6 stimulation and serves as a readily available readout of systemic inflammation. Hepatic and renal abnormalities reflect both direct inflammatory organ injury and the hemodynamic consequences of vasodilatory shock, in which reduced perfusion compounds cytokine-mediated tissue damage.

Treatment in the collected cases followed two main pillars: discontinuation of nivolumab and immunosuppressive or immunomodulatory therapy directed at the cytokine cascade itself. Glucocorticoids and tocilizumab, a monoclonal antibody that blocks the interleukin-6 receptor, were widely utilized as the primary therapeutic approaches. After these interventions, 71.4 percent of patients showed improvement in symptoms and clinical markers. The remaining 28.6 percent died. That mortality figure, drawn from published case reports that may overrepresent severe presentations, nevertheless signals that nivolumab-induced cytokine release syndrome can lead to multi-organ functional impairment and can be fatal. The authors emphasize that the syndrome is not a benign infusion reaction but a potentially life-threatening emergency requiring prompt recognition.

The choice of tocilizumab as first-line therapy reflects experience imported from the CAR T-cell field, where interleukin-6 receptor blockade has become standard for severe cytokine release syndrome and is embedded in consensus grading systems such as the ASTCT criteria and in clinical practice guidelines from the Society for Immunotherapy of Cancer and the American Society of Clinical Oncology. Glucocorticoids, which broadly suppress T-cell and macrophage activation, are typically layered on when tocilizumab alone is insufficient or when neurological symptoms are present. For refractory cases, the broader literature on immune effector cell toxicities describes additional salvage options, including plasma exchange, but the evidence base for such measures in checkpoint inhibitor-associated CRS remains thin and largely anecdotal.

Herein lies the central limitation the authors acknowledge: the standardized and optimal treatment strategy for nivolumab-induced cytokine release syndrome remains undefined. Because the analysis is retrospective and built from individually published case reports, it is vulnerable to reporting bias, inconsistent grading and inherent clinical confounders. Patients described in case reports are often the sickest, which may inflate the apparent mortality, and concomitant medications, infections, combination immunotherapy regimens and underlying malignancies can all mimic or exacerbate the syndrome. The researchers also note that the available evidence base is limited, meaning that while glucocorticoids and tocilizumab are the de facto standards in clinical practice, no prospective trial has defined the ideal timing, dosing or sequencing of these agents specifically for nivolumab-triggered CRS.

The mechanistic puzzle is also unresolved. Nivolumab blocks programmed death-1, a checkpoint receptor that restrains T-cell activity, and cytokine release syndrome after checkpoint blockade is thought to arise when reinvigorated T cells expand and secrete interferon and other mediators that activate macrophages and endothelial cells. Why only a small fraction of the many thousands of patients treated with nivolumab develop this syndrome is unknown, though prior pharmacovigilance analyses of WHO data and case series of checkpoint inhibitor-associated CRS suggest the event is rare and may be more frequent with combination regimens such as ipilimumab plus nivolumab. Host genetic factors influencing interleukin-6 biology, tumor burden, and individual immune repertoire dynamics are plausible contributors that current data cannot disentangle.

For clinicians, the practical takeaways are concrete. Fever developing during nivolumab therapy, particularly when accompanied by hypotension, tachycardia, rash or confusion, should prompt evaluation for cytokine release syndrome rather than automatic attribution to infection or tumor progression. Measurement of C-reactive protein, ferritin and interleukin-6 can support the diagnosis, and early involvement of intensive care may be warranted given the risk of hemodynamic collapse and multi-organ failure. For researchers, the study defines the agenda: prospective registries, standardized grading using consensus CRS criteria, and controlled evaluation of tocilizumab and corticosteroid protocols are needed to move management from case-report empiricism to evidence-based practice. Until then, vigilance remains the most powerful tool, because the window in which glucocorticoids and interleukin-6 blockade can reverse the inflammatory cascade is likely narrow, and the price of missing it, in roughly one of the patients captured in this analysis, was fatal.

Subject of Research: Cytokine release syndrome induced by the immune checkpoint inhibitor nivolumab

Article Title: Clinical characteristics, treatment and prognosis of nivolumab induced cytokine release syndrome

Article References: Zhao, S., Sun, W., Peng, L., & Wang, C. (2026). Clinical characteristics, treatment and prognosis of nivolumab induced cytokine release syndrome. Supportive Care in Cancer, 34(10), Article 1039. https://doi.org/10.1007/s00520-026-11303-8

Image Credits: AI Generated

DOI: 10.1007/s00520-026-11303-8

Keywords: nivolumab, cytokine release syndrome, immune checkpoint inhibitors, tocilizumab, glucocorticoids, interleukin-6, immune-related adverse events, ferritin, hypotension, immunotherapy toxicity, PD-1 inhibitor, retrospective analysis

The biology of CRS begins the moment engineered T cells recognize their target. CAR T cells are autologous lymphocytes genetically modified to express synthetic receptors that bind tumor-associated antigens such as CD19 or BCMA. Upon antigen engagement, the cells unleash perforin and granzyme to kill malignant cells while simultaneously secreting a cocktail of pro-inflammatory signaling proteins, including interferon-gamma, tumor necrosis factor alpha, GM-CSF, and interleukin-2. These signals then recruit and activate innate immune players, chiefly monocytes and macrophages, which respond by pouring out interleukin-6 and interleukin-1 beta. This amplification loop between adaptive and innate immunity is what transforms a targeted attack into a systemic cytokine storm. Vascular endothelial cells become activated, blood vessels leak, and patients develop the classic clinical picture: fever, fatigue, hypotension, hypoxia, and in the worst cases multi-organ dysfunction. In severe instances, the syndrome can escalate into an immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome and contribute to disruption of the blood-brain barrier, setting the stage for neurological complications.

How sick a patient becomes is not a matter of chance. Tumor burden at baseline, the specific CAR construct used, and the magnitude of T-cell expansion all shape the intensity of the inflammatory response. The intracellular costimulatory domain built into the receptor plays a particularly important role: constructs carrying the CD28 domain drive rapid T-cell expansion and are associated with a higher incidence of acute, severe adverse events, whereas 4-1BB-based constructs expand more slowly and persistently, producing a more gradual and generally less toxic immune response. Higher CAR T-cell doses enhance antitumor efficacy but also raise the risk of massive simultaneous T-cell activation. Patient factors matter as well. Elevated pre-infusion inflammatory markers such as interleukin-6 and C-reactive protein, advanced age, cardiovascular or renal comorbidities, certain lymphoma subtypes including primary mediastinal B-cell lymphoma, and pediatric or young adult patients treated for acute lymphoblastic leukemia all signal elevated risk. Bridging therapy to shrink the tumor before infusion is one practical strategy to lower the odds of explosive cytokine release.

Accurate grading is the backbone of treatment decisions. The consensus system from the American Society for Transplantation and Cellular Therapy classifies CRS into four grades based on fever, hypotension, hypoxia, and organ toxicity, deliberately moving beyond fever alone to incorporate the need for vasopressors and supplemental oxygen. Grade 1 disease, essentially fever by itself, is usually managed conservatively with antipyretics and observation. Grade 2, marked by hypotension or mild hypoxia, requires hospital monitoring and often pharmacologic intervention. Grade 3 and 4 cases, involving refractory low blood pressure, multisystem injury, shock, or respiratory failure, demand escalation to corticosteroids, vasopressors, and intensive care, with mechanical ventilation reserved for the critically ill. Because the boundary between CRS and sepsis can be blurred, clinicians must constantly weigh early immunosuppression against the danger of masking an underlying infection, a balancing act that defines much of the day-to-day management of these patients.

At the center of the pharmacologic arsenal sits tocilizumab, a monoclonal antibody that blocks the interleukin-6 receptor and remains the only drug approved by the FDA specifically for CRS. By interrupting the interleukin-6 signaling axis, it rapidly reverses fever, hypotension, and capillary leak without impairing the antitumor activity of the CAR T cells, and in most patients one or two doses suffice to control grade 2 or higher disease. Its speed has made it the emergency drug of choice, stocked in treatment centers with STAT ordering protocols. But tocilizumab is not without caveats. Blocking the receptor can cause circulating interleukin-6 levels to rebound, and there is concern that unbound cytokine may then cross the blood-brain barrier, potentially triggering or worsening immune effector cell-associated neurotoxicity syndrome, known as ICANS. This interplay between the two syndromes complicates therapy, since ICANS typically emerges days after CRS onset and, unlike CRS, does not respond to tocilizumab because the antibody penetrates the central nervous system poorly.

For patients who fail interleukin-6 blockade or who develop neurological symptoms, corticosteroids such as dexamethasone and methylprednisolone serve as the crucial second line. Historical worries that steroids might blunt CAR T-cell proliferation have been tempered by more recent evidence showing that early administration at moderate doses and limited duration does not significantly compromise antitumor efficacy. Typical regimens involve intravenous dexamethasone at 10 milligrams every six hours or methylprednisolone at 1 to 2 milligrams per kilogram per day, tapered over three to five days according to clinical response. Beyond steroids, a growing set of targeted agents is expanding the toolkit. Anakinra, an interleukin-1 receptor antagonist, crosses the blood-brain barrier readily and is increasingly valued for tocilizumab-refractory CRS and concurrent neurotoxicity. Lenzilumab, targeting GM-CSF, and emapalumab, targeting interferon-gamma, are under clinical evaluation for severe or steroid-refractory disease. In a striking example of drug repurposing, the beta-blocker metoprolol has been shown in laboratory and clinical studies to directly inhibit interleukin-6 translation in human monocytes, reducing CRS severity without harming CAR T-cell function and opening a novel therapeutic target: the protein synthesis machinery of inflammatory cells.

Monitoring is where modern CRS care increasingly meets data science. Routine protocols call for daily ferritin, C-reactive protein, and cytokine panels during the first ten days after infusion, or longer in high-risk patients, because rising interleukin-6, ferritin, and CRP levels precede clinical symptoms and correlate with severity. Soluble interleukin-2 receptor and coagulation markers flag the hemophagocytic syndrome variant and coagulopathy. Artificial intelligence is now pushing surveillance further. A model called PrCRS, built on U-Net and Transformer architectures with transfer learning, can predict severe CRS one to three days before symptom onset. Other multimodal machine learning systems analyze vital signs, laboratory results, and early cytokine profiles to identify high-risk patients within hours of infusion, and an explainable algorithm proposed by Bogatu and colleagues incorporates domain literature to detect CRS from cytokine peak levels despite limited training data. Real-time dashboards linked to electronic health records are already being piloted at academic centers, alerting care teams and enabling preemptive tocilizumab or steroid administration based on algorithmic triggers.

None of these tools work in isolation, and the review emphasizes that the hallmark of contemporary CRS management is multidisciplinary coordination. Optimal outcomes emerge when hematologists, oncologists, intensivists, neurologists, infectious disease specialists, pharmacists, and specialized nurses operate under unified protocols with rapid triage pathways and seamless escalation from ward to intensive care. Many centers have established cellular therapy toxicity boards, early warning systems, and dedicated CAR T-cell response teams equipped with predesigned protocols, immediate drug access, and intensive care beds on standby. Standardized operating procedures embed CRS and ICANS flowcharts directly into electronic medical records, while simulation training for nurses and residents sharpens recognition of early warning signs. Age also shapes strategy: pediatric patients generally tolerate higher cytokine loads, so clinicians lean on supportive care and reserve steroids for refractory cases, whereas elderly patients, vulnerable to cardiovascular and renal decompensation, warrant a lower threshold for early intervention, cardiac monitoring, and bridging therapy to reduce disease burden before infusion.

Looking ahead, the field is moving from reactive treatment to engineered prevention. Ruxolitinib, a Janus kinase 1/2 inhibitor, dampens downstream signaling from multiple cytokines and may help when interleukin-6 blockade alone is insufficient. Siltuximab, which binds interleukin-6 directly rather than its receptor, offers an alternative where receptor blockade falls short. More radically, next-generation CAR constructs are being designed with safety built in: bispecific and split-signaling receptors that require dual-antigen recognition to activate, ON/OFF-switch systems controlled by administered small molecules, suicide genes such as inducible caspase 9, and so-called armored CARs that co-express anti-cytokine payloads like interleukin-1 receptor antagonists to neutralize inflammation at its source. Researchers are also probing the upstream triggers of CRS, implicating inflammasome activation, pyroptotic cell death, and tissue-resident macrophages, and pursuing multi-omics biomarker discovery to shift management from reactive to proactive. Together, these advances promise to widen the therapeutic window of CAR T-cell therapy, allowing its remarkable curative potential to reach broader and more fragile patient populations safely.

Subject of Research: Management of cytokine release syndrome following CAR T-cell therapy

Article Title: Management of Cytokine Release Syndrome (CRS) following CAR T-cell therapy: a comprehensive review

Article References: Zhang, Y., & Han, W. (2025). Management of Cytokine Release Syndrome (CRS) following CAR T-cell therapy: a comprehensive review. Clinical Cancer Bulletin, 4(1), Article 15. https://doi.org/10.1007/s44272-025-00044-0

Image Credits: AI Generated

DOI: 10.1007/s44272-025-00044-0

Keywords: CAR T-cell therapy, cytokine release syndrome, tocilizumab, ICANS, immunotherapy toxicity, interleukin-6, corticosteroids, anakinra, biomarkers, artificial intelligence prediction, risk stratification, hematological malignancies

Meredith’s treatment history traces the modern arc of myeloma therapy. She began with the standard triplet of bortezomib, lenalidomide, and dexamethasone, gaining weight from the steroid but otherwise feeling relatively normal, before undergoing an autologous stem cell transplant in December 2019. That transplant proved grueling: a two-week hospitalization in Milwaukee, a three-hour drive from her hometown, and three to four weeks living within a 45-minute radius of the hospital afterward. She spent her birthday in a motel. Maintenance lenalidomide followed, but she relapsed roughly two years after diagnosis, moving on to daratumumab and carfilzomib, a combination that triggered fevers, facial swelling, emergency room visits, and repeated admissions for sepsis. A second relapse in March 2022 led to elotuzumab, pomalidomide, and dexamethasone, and her disease progressed again within months.

The commentary accompanying her account notes that Meredith’s disease moved faster than typical. In one analysis of United States electronic health records, the median time from first treatment to a second regimen was 46.7 months, and in a referral-center study the median time to a third treatment in relapsed patients was 16.6 months, both roughly twice the pace of Meredith’s progression. In a clinical study of daratumumab, carfilzomib, and dexamethasone, serious infections occurred in 19 percent of patients, but sepsis was not reported, underscoring how individual responses to the same regimens can diverge sharply from trial averages.

With few options remaining, Meredith enrolled in a clinical trial of chimeric antigen receptor T cell, or CAR-T, therapy in 2022. Bridged with daratumumab, bortezomib, and dexamethasone while increasingly ill, she received the engineered cells and spent four weeks hospitalized, developing severe cytokine release syndrome, a systemic inflammatory reaction in which immune cells flood the bloodstream with signaling proteins, that required several days in the intensive care unit. A later readmission for neutropenic fever followed. Recovery took months, but she emerged symptom- and treatment-free for 18 months, until May 2024, when a lesion on her sternum signaled yet another relapse. Her hematologist recommended talquetamab, a bispecific antibody she had never heard of, and with no clinical trials available to her, she agreed to try it.

Talquetamab works differently from CAR-T. It is a bispecific antibody that redirects T cells against GPRC5D, a protein abundant on myeloma cells, and it is approved for triple-class exposed relapsed/refractory multiple myeloma. Nurse practitioner Donna Catamero, who cares for myeloma patients at a large academic center and whose hospital enrolled the first patient on talquetamab monotherapy in the pivotal MonumenTAL-1 trial, describes two ideal candidates: patients needing a bridge to CAR-T therapy, and patients like Meredith who relapse while on a B cell maturation antigen, or BCMA, directed therapy such as a CAR-T product or a BCMA-targeting bispecific. In this heavily pre-treated population, she reports, complete remissions with durable responses have been observed, something rarely seen before in patients with so many prior therapies.

The drug’s side effect profile is distinctive because GPRC5D is also expressed in normal tissues. In MonumenTAL-1, cytokine release syndrome occurred in 75 to 79 percent of patients, but most events were low grade, occurred at or before the first full dose, and resolved, which is why step-up dosing and mandatory hospitalization during the initial doses are built into the treatment protocol. More than 70 percent of patients experience taste changes, and dry mouth, weight loss, rash, skin disorders, and nail changes are common. Skin and taste problems tend to appear within three to four weeks, while weight and nail changes develop more slowly. Rashes generally resolve within weeks, but taste, nail, and weight changes often persist, with modest improvement over time in most patients.

Meredith experienced this profile firsthand. She spent two weeks hospitalized at the start of treatment and had cytokine release syndrome, from which she recovered before discharge. Severe itching and red blotches on her face and body emerged first, managed with daily baths with bathing salts, allergy medications, and alcohol-free medical creams, resolving after five to six weeks. Nail discoloration and transient blurred vision followed. She lost 45 pounds during treatment, and the most burdensome effects were taste changes and dry mouth, which she managed by experimenting with cold liquids such as popsicles, ice cream, and smoothies, and soft foods including applesauce, mashed potatoes, pasta, and fish. After three to four months the side effects decreased substantially, and she is now in month 19 of treatment, feeling better emotionally and physically than she did after CAR-T.

The clinical machinery behind these outcomes is elaborate. Catamero’s team educates patients and care partners about cytokine release syndrome symptoms, including fever and hypotension, monitors vital signs every four to six hours during step-up dosing, and deploys intravenous fluids, oxygen, antipyretics, and, when needed, the interleukin-6 inhibitor tocilizumab or steroids. The US label advises that doses may be delayed to manage oral toxicity, and reducing dose frequency after a response is achieved has proven helpful and is supported by trial evidence. Dietitian Isabelle Wlodkowski provides mandatory nutrition consultations during the hospital stay, counseling patients on high-calorie, high-protein strategies, eight to ten cups of fluid daily for dry mouth, sugar-free gum, small frequent meals, and home weight tracking. A phase 2 study called TALISMAN is now using an objective instrument, the Waterless Empirical Taste Test, which preliminary results suggest can detect taste changes earlier than patient self-report and capture improvement as early as three months after treatment begins.

The transition from inpatient to outpatient care is where the multidisciplinary model earns its keep. Catamero emphasizes laboratory monitoring for infections and cytopenias, prophylaxis strategies, rapid pathways for evaluating fever, and proactive screening for skin and oral toxicities that patients often under-report until advanced. A safe handoff between a specialist center and a community oncologist depends on an explicit shared care plan covering dose schedules, prior cytokine release syndrome or neurotoxicity grades, 24/7 triage phone numbers, and shared toxicity algorithms. Patient advocate Becky Bosley of the International Myeloma Foundation stresses preparation for the hospitalization required during step-up doses, including delegating family and work responsibilities and planning financially for copays, and points to the foundation’s more than 150 myeloma-specific support groups and its AI-powered chatbot, Myelo, which answers questions using only information from myeloma.org.

Meredith’s care now spans a myeloma specialist, a local hematologist-oncologist, cancer nurses, a nutritionist, and an in-house patient advocate, with nursing staff having arranged treatment at a facility closer to home to ease the burden of traveling every other week. Her husband attends nearly every appointment, and she belongs to local and Mayo Clinic-affiliated support groups while following educational programming from the International Myeloma Foundation, the Multiple Myeloma Research Foundation, the Leukemia & Lymphoma Society, and the American Cancer Society. Her light chain lab values have been stable at every visit, her advice to new patients is to give the treatment six to eight weeks before judging it, and she teaches voice lessons, gardens, and exercises again. Her story illustrates a central message of the perspective: in relapsed myeloma, the drug is only half the treatment, and the coordinated team around it is what keeps patients on therapy and living well.

Subject of Research: Patient and clinician perspectives on living with relapsed/refractory multiple myeloma and multidisciplinary management of talquetamab therapy

Article Title: Perspectives on Living with Relapsed/Refractory Multiple Myeloma and Multidisciplinary Care from a Patient, Nurse Practitioner, Dietitian, and a Patient Advocate

Article References: Bosley, B., Wlodkowski, I., Catamero, D., & Meredith, S. (2026). Perspectives on Living with Relapsed/Refractory Multiple Myeloma and Multidisciplinary Care from a Patient, Nurse Practitioner, Dietitian, and a Patient Advocate. Advances in Therapy. https://doi.org/10.1007/s12325-026-03801-2

Image Credits: AI Generated

DOI: 10.1007/s12325-026-03801-2

Keywords: multiple myeloma, relapsed/refractory myeloma, talquetamab, bispecific antibodies, CAR-T therapy, cytokine release syndrome, GPRC5D, dysgeusia, supportive care, oncology nutrition, patient advocacy, multidisciplinary care

Hepatocellular carcinoma ranks as the sixth most common cancer worldwide and the fourth leading cause of cancer death, a grim combination that reflects both late diagnosis and limited options once the disease spreads. For patients with advanced disease, five-year survival remains persistently low, and the standard arsenal of tyrosine kinase inhibitors, immune checkpoint inhibitors, and locoregional procedures such as radioembolization and hepatic arterial infusion chemotherapy frequently buys only months. Adoptive cell transfer immunotherapy, in which a patient’s own lymphocytes are harvested, genetically reprogrammed, and reinfused, has transformed the treatment of several blood cancers, but solid tumors have proven far more resistant. TCR-engineered T cell therapy represents one of the most sophisticated attempts to crack that problem: rather than recognizing surface proteins through a chimeric antigen receptor, as CAR-T cells do, TCR-T cells are equipped with a natural T cell receptor that can detect peptide fragments presented inside cells by human leukocyte antigen molecules, vastly expanding the range of targetable antigens.

The choice of target in this case was elegant in its logic. Because the patient’s tumor arose in the context of chronic hepatitis B infection, many of his malignant cells carried integrated hepatitis B DNA and continued to produce the viral surface antigen, HBsAg. By engineering his T cells with a receptor specific for HBsAg-derived peptides, the therapeutic team aimed to convert a persistent viral infection into a tumor-specific bullseye, sparing healthy hepatocytes that do not present the antigen. The strategy exploits a biological quirk of hepatitis B-related liver cancer that simply does not exist in tumors of other origins, and it illustrates how viral oncogenesis can be turned against the cancer itself.

The patient’s medical history underscores how heavily pretreated he was before receiving the experimental cells. Diagnosed with hepatocellular carcinoma in April 2018 after laparoscopic resection, he had been maintained on antiviral therapy, first entecavir and later tenofovir alafenamide fumarate after renal function declined. When his alpha-fetoprotein tumor marker rose in June 2022, imaging revealed retroperitoneal lymph node metastases, which were attacked with stereotactic body radiotherapy and CT-guided iodine-125 seed brachytherapy. Systemic therapy followed in force: three different tyrosine kinase inhibitors, three immune checkpoint inhibitors including the bispecific antibody cadonilimab, and eventually FOLFOX4 hepatic arterial infusion chemotherapy for recurrent intrahepatic lesions. None of it held the line. By July 2024, PET-CT showed new metastases in cervical and supraclavicular lymph nodes, the lungs, and the pelvic bones, and the patient was enrolled in an HBsAg-targeted TCR-T clinical trial classified as stage IIIB with preserved liver function.

The manufacturing and administration protocol followed the now-standard architecture of adoptive cell therapy. Mononuclear cells were collected by apheresis on August 9, 2024, and seventeen days later the patient received a lymphodepleting preconditioning regimen of cyclophosphamide and fludarabine, the latter dose-adjusted from 25 to 20 milligrams per square meter per day because of his reduced creatinine clearance. He then received an intravenous infusion of autologous TCR-T cells at a dose of 1 times 10 to the eighth cells per kilogram, totaling 5.64 billion TCR-positive T cells. Within two hours, the inflammatory cascade began: fever spiking to 39.7 degrees Celsius, chills, falling oxygen saturation, chest tightness, nausea, and vomiting. The clinical team graded his cytokine release syndrome using the National Cancer Institute’s CTCAE v5.0 criteria and initiated oxygen, fluids, antipyretics, empiric antibiotics, and the interleukin-6 blocker tocilizumab at five and thirteen hours post-infusion.

By the first day, the syndrome had escalated to grade 3. His blood pressure dropped to 96 over 53 millimeters of mercury from a baseline of 135 to 150 over 70 to 80, fluid output fell behind intake, and serum creatinine climbed, prompting low-dose norepinephrine and a third dose of tocilizumab at thirty hours. Blood pressure recovered within two hours and the vasopressor was weaned, but the picture that followed was textbook capillary leak syndrome: purpura across the lower limbs, axillae, and chest, pitting edema, diminished breath sounds, and CT evidence of mild pulmonary edema with bilateral pleural effusions. The physicians managed the leakage phase with deliberately restrained fluid resuscitation, favoring albumin-containing solutions to maintain oncotic pressure, and then pivoted to aggressive diuresis during the reabsorption phase to prevent fluid overload. Temperature stabilized by day five, and fatigue and dyspnea resolved within two weeks. Laboratory markers told a parallel story, with C-reactive protein peaking at 21.9 milligrams per liter, ferritin hitting the detection ceiling on day one, and interleukin-6 cresting on day one before falling steadily from day three.

The hematologic toxicity was, if anything, more severe than the inflammatory syndrome. Lymphocyte counts predictably collapsed after lymphodepletion, but white cells and neutrophils also plunged to grade 4 and grade 3 respectively by day one. Encouragingly, recovery began without granulocyte colony-stimulating factor, with leukocytes rebounding on day three and neutrophils on day seven, both reaching grade 2 severity by day fourteen, a pattern the authors classify as rapid recovery and one that suggests preserved bone marrow reserve. Hemoglobin, already low before infusion, bottomed out at 71 grams per liter on day four, and platelets dipped to grade 2 between days three and six before returning to baseline by day 87. Transaminases followed an inverted V-shaped curve, with grade 4 ALT and AST elevations downgrading within seven days, while cholestatic enzymes remained stable. Coagulation studies revealed a consumptive pattern, with D-dimer surging to 22.89 milligrams per liter alongside falling fibrinogen and mildly prolonged partial thromboplastin time, consistent with cytokine-driven endothelial activation and microthrombosis; the D-dimer fell by half within four days and anticoagulation was withheld.

The therapeutic signal, though transient, was genuine. At six weeks, imaging showed slight shrinkage of the cervical lymph node and lung metastases, although bone lesions continued to grow and a partial response was not achieved under modified RECIST 1.1 criteria. Alpha-fetoprotein, which had climbed to 1,575 nanograms per milliliter before infusion, fell to 413 by day eleven before rebounding. TCR-T cells were detectable in peripheral blood from day four, when they peaked, until week six. Most strikingly, HBsAg levels dropped to nearly undetectable concentrations by day seven, a direct pharmacodynamic readout confirming that the engineered cells were striking their viral target, while hepatitis B viral DNA, initially suppressed below the detection limit, rose again at week six in synchrony with tumor progression. By day 87, every lesion had progressed. The patient later suffered lacunar infarcts in the pons and left posterior ventricular horn, a rare complication the authors attribute cautiously to cytokine-mediated hypercoagulability and cerebral hypoperfusion, though his pre-existing hypertension and diabetes confound any causal attribution. Palliative radiotherapy and chemotherapy followed, and after malignant obstruction of the inferior vena cava required stenting, he entered hospice care in late February 2025 and died two weeks later.

The authors draw several sobering lessons from the trajectory. Solid tumors present barriers that hematologic malignancies do not: engineered T cells accumulate first in the lungs and lymphoid organs and migrate inefficiently into tumor masses, which may explain the transient regression of lymph node lesions, while the relentless progression of bone metastases suggests the cells never meaningfully infiltrated osseous tissue, a compartment for which no tracking data yet exist. On the safety side, the case demonstrates that TCR-T toxicity mirrors the well-mapped CAR-T experience, with grade 3 to 4 cytopenias occurring at rates comparable to published CAR-T series, where neutropenia affects 59 to 95 percent of patients, and that capillary leak syndrome demands a disciplined, phase-specific fluid strategy. The report concludes that HBsAg-targeted TCR-T therapy for advanced hepatocellular carcinoma carries a tolerable, controllable safety profile when grade 3 cytokine release syndrome and hematologic toxicity are monitored closely, even as the modest and short-lived antitumor effect makes clear that improving cell persistence, trafficking, and bone infiltration remains the decisive challenge for this promising but still immature modality.

Subject of Research: HBsAg-targeted TCR-engineered T cell therapy for advanced hepatocellular carcinoma

Article Title: Treatment of advanced hepatocellular carcinoma with HBsAg-targeted TCR engineered -T Cells: a case report

Article References: Wei, S., Gu, L., Shi, J., & Wang, W. (2025). Treatment of advanced hepatocellular carcinoma with HBsAg-targeted TCR engineered -T Cells: a case report. Clinical Cancer Bulletin, 4(1), Article 19. https://doi.org/10.1007/s44272-025-00048-w

Image Credits: AI Generated

DOI: 10.1007/s44272-025-00048-w

Keywords: hepatocellular carcinoma, TCR-T cell therapy, HBsAg, cytokine release syndrome, capillary leak syndrome, adoptive cell transfer, hematologic toxicity, hepatitis B, immunotherapy, case report, solid tumors, tocilizumab

The mechanistic elegance of CAR-T therapy explains much of its success. Researchers harvest T lymphocytes and genetically equip them with synthetic receptors whose extracellular portions, typically single-chain variable fragments, bind specific antigens on malignant cells. When the receptor engages its target, intracellular signaling domains transmit activation signals through immunoreceptor tyrosine-based activation motifs in the CD3ζ chain, recruiting kinases such as LCK and ZAP70 that ignite three core pathways: MAPK, PI3K-Akt, and NF-κB. Costimulatory domains like CD28 or 4-1BB amplify and sustain these signals, and the activated cells then kill through two parallel strategies: perforin and granzyme punch pores in target cells to trigger apoptosis, while death receptor binding via FAS/FASL and TRAIL activates extrinsic cell death. Inflammatory cytokines such as interferon-gamma and tumor necrosis factor-alpha add a broader anti-tumor push. Five successive generations of CAR designs have built on this foundation, from first-generation constructs with only the CD3ζ domain to fifth-generation cells incorporating cytokine receptor signaling modules and logic-gated architectures.

But the therapy’s power comes with a dangerous edge. Cytokine release syndrome, the best-known toxicity, arises when activated CAR-T cells flood the body with pro-inflammatory cytokines including IL-1, IL-6, and interferon-gamma, potentially progressing to multiorgan dysfunction and death. In one study of CD70-directed allogeneic CAR-T therapy, 67 percent of patients experienced CRS, including one grade 4 dose-limiting toxicity. Immune effector cell-associated neurotoxicity syndrome, or ICANS, ranges from mild confusion to severe seizures, and emerging evidence points to cytokine-mediated endothelial activation and blood-brain barrier disruption. A pediatric cohort study documented five cases of acute quadriparesis and paraparesis with demyelinating lesions on MRI and elevated neurofilament light chain in cerebrospinal fluid, but no leukocytic infiltration, revealing a distinct neurotoxicity phenotype. Standard management relies on the IL-6 receptor blocker tocilizumab and corticosteroids, though these agents can suppress the very T cells doing the therapeutic work, a paradox that has spurred engineering of CAR-T cells with IL-6 or interferon-gamma silenced via shRNA.

Solid tumors present an even more formidable fortress. The tumor microenvironment combines physical barriers, including dense extracellular matrix and disorganized vasculature that impairs T cell extravasation, with an immunosuppressive cellular landscape of myeloid-derived suppressor cells, regulatory T cells, and M2-polarized macrophages. Hypoxia, acidosis, and metabolic competition further drain CAR-T cell fitness. Tumors also deploy cell-intrinsic defenses: spatial and temporal heterogeneity in antigen expression, confirmed by single-cell RNA sequencing across tumor subregions, allows antigen-negative subclones to escape under therapeutic pressure, while checkpoint ligands such as PD-L1 and B7-H3 drive T cell exhaustion. On-target off-tumor toxicity compounds the danger, since many solid tumor antigens also appear on healthy tissue. Researchers are responding with affinity-tuned binders, logic-gated and dual CAR designs, and synthetic biology circuits that demand multiple simultaneous signals before the cells attack, aiming for precision that spares normal tissue.

T cell exhaustion itself has become a molecular battleground. Transcription factors TOX, TOX2, and NR4A family members program the exhausted state, regulated by NFAT acting even without its AP-1 partner. Exhausted cells upregulate inhibitory receptors including PD-1, TIM3, and LAG-3, suffer impaired mitochondrial function and suppressed glycolysis, and lose proliferative capacity. Tumor-derived extracellular vesicles can push CAR-T cells into this dysfunctional state by inducing supraphysiologic inflammation. Countermeasures are emerging: overexpression of c-Jun confers exhaustion resistance and enhances expansion, inhibition of sphingosine 1-phosphate receptor 3 remodels the microenvironment and improves infiltration, and MEK inhibitors downregulate c-Fos and JunB to prevent exhaustion-driven differentiation. These interventions, combined with checkpoint inhibitors, aim to keep engineered cells in a persistent, cytotoxic, stem-like state.

Engineering innovation is accelerating on every front. Charge density modulation of the CAR antigen-binding domain optimizes tonic signaling and reduces spontaneous activation, while endogenous signaling molecule activating CARs recruit native signaling molecules through their transmembrane domains, showing promise against triple-negative breast cancer with less cytokine release than conventional designs. Armored CAR-T cells secrete payloads directly into the tumor: IL-15 and CCL19-secreting cells show enhanced efficacy in glioblastoma models, Serpin B9-armored cells resist granzyme B-mediated fratricide, FOXP3-coexpressing cells acquire stem-like durability, and TIM-3-Fc decoy secretion improves CD19 CAR-T therapy in B-ALL by neutralizing galectin-9. Synthetic Notch receptors enable conditional CAR expression only when cells encounter tumor vascular markers like P-selectin, creating microenvironment-actuated T cells that improve selectivity while preserving potency. Multivalent ELECTRIC CARs targeting KIT, MPL, and FLT3 simultaneously offer a non-genotoxic conditioning strategy for leukemia, and tri-functional M10 cells designed against HIV-1 combine cytotoxicity, viral neutralization, and B-cell follicle homing.

Perhaps the most disruptive shift involves manufacturing. Autologous CAR-T production remains slow, complex, and costly, often exceeding $400,000 per patient, with a median 108 days from consultation to infusion in community networks and 41 percent of patients unable to access timely therapy. Universal off-the-shelf products derived from healthy donors promise immediate availability and consistent quality, with CRISPR/Cas9 knockout of TCR and HLA genes mitigating graft-versus-host disease and host-versus-graft rejection. Mucosal-associated invariant T cells, which do not mediate alloreactivity, offer an allogeneic source requiring minimal genetic modification. Even more radical is in vivo CAR-T generation: delivering viral vectors or targeted lipid nanoparticles encoding the CAR construct directly into the patient, reprogramming circulating T cells in situ and eliminating ex vivo manipulation entirely. Recent work has demonstrated in vivo generation of functional CAR-T cells for cancer and autoimmune disease, though vector immunity, insertional mutagenesis risk, and dosing control remain unsolved.

Clinical results are now extending well beyond blood cancers. Claudin 18.2-targeted CAR-T cells achieved a 38.8 percent overall response rate and 91.8 percent disease control rate in gastrointestinal cancers, with 96.9 percent of patients experiencing only grade 1-2 CRS and no treatment-related deaths. GD2-directed cells delivered a 63 percent response rate in high-risk neuroblastoma with three-year overall survival reaching 60 percent, while CD70-targeted allogeneic cells produced an 81.3 percent disease control rate in clear cell renal cell carcinoma. In multiple myeloma, the dual BCMA/CD19 construct GC012F achieved a 100 percent response rate with 95.5 percent complete remission. Most strikingly, CD19 CAR-T therapy is rewriting the playbook for autoimmune disease: a German cohort achieved 100 percent drug-free remission in 15 refractory autoimmune patients, and universal CD19 CAR-T cells reversed skin fibrosis in systemic sclerosis patients, with one regaining finger mobility within days of infusion, challenging the assumption that fibrotic damage is irreversible.

The review’s authors frame the future around three strategic priorities: optimized CAR design, combination therapies, and scalable manufacturing. Gene editing with CRISPR enzymes such as PcoCas12a can knock out negative regulators like DGKα to boost anti-tumor function, while deletion of NR4A factors, CTLA-4, or the adenosine A2A receptor enhances persistence in hypoxic tumor niches. Combinations with pembrolizumab, ibrutinib, oncolytic viruses, and STING agonists aim to convert immunologically cold tumors into hot ones, and automated bioreactors, non-viral gene transfer, and point-of-care manufacturing promise to slash costs and timelines. Applications in infectious disease, where bNAb-derived CAR-T cells have reduced HIV reservoirs, and in fibrosis and senescence, where senolytic CAR-T cells target age-related dysfunction, suggest the platform may ultimately transcend oncology altogether. What began as a last-resort therapy for dying leukemia patients is evolving into a versatile system of precision immune reprogramming, one whose full scope researchers are only beginning to map.

Subject of Research: Advances, challenges, and clinical breakthroughs of CAR-T cell therapy in refractory cancers and beyond

Article Title: Advances in CAR-T cell therapy for refractory diseases: challenges, innovations, clinical breakthroughs, and future prospects

Article References: Liao, Q., Mao, Y., Feng, M., Zheng, N., Ding, X., Zhang, X., Wang, Z., & Xu, J. (2025). Advances in CAR-T cell therapy for refractory diseases: challenges, innovations, clinical breakthroughs, and future prospects. Clinical Cancer Bulletin, 4(1), Article 21. https://doi.org/10.1007/s44272-025-00050-2

Image Credits: AI Generated

DOI: 10.1007/s44272-025-00050-2

Keywords: CAR-T cell therapy, immunotherapy, solid tumors, cytokine release syndrome, CRISPR gene editing, autoimmune disease, hematological malignancies, tumor microenvironment, off-the-shelf CAR-T, in vivo CAR-T, T cell exhaustion, cell therapy manufacturing

CAR T-cell therapy has reshaped the treatment landscape for relapsed and refractory multiple myeloma. The approach involves collecting a patient’s own T-lymphocytes, engineering them in the laboratory to express a chimeric antigen receptor that recognizes a specific target on cancer cells, expanding the modified cells to large numbers, and reinfusing them into the patient. In myeloma, the preferred target is B cell maturation antigen, or BCMA, a protein abundantly expressed on malignant plasma cells. Two such products, idecabtagene vicleucel and ciltacabtagene autoleucel, have demonstrated high initial response rates in clinical trials and are now established options for patients whose disease has exhausted conventional therapies.

Despite those impressive early results, a major clinical challenge looms: relapse. Most patients who respond to BCMA-directed CAR T-cell therapy eventually experience disease progression, and once that happens, therapeutic options become scarce and prognosis is often poor. Whether a second BCMA-directed CAR T-cell infusion can work after the first one has failed has remained an open question, complicated by concerns that the tumor may have evolved mechanisms of immune escape, including loss or downregulation of the BCMA target itself.

The newly reported case offers a carefully documented data point. The patient had high-risk IgA kappa multiple myeloma and had undergone extensive prior treatment. Idecabtagene vicleucel was administered as his sixth line of therapy, and it produced a deep response lasting approximately one year. When his disease subsequently progressed, the clinical team faced the dilemma of how to bridge him to a potential second cellular therapy while keeping the myeloma under control. Notably, whole genome sequencing performed earlier had confirmed that his myeloma cells still expressed BCMA, providing a molecular rationale for retargeting the same antigen with a different CAR construct.

As bridging therapy, the patient received a combination of mezigdomide, carfilzomib, and dexamethasone. Mezigdomide belongs to the CELMoD class, a new generation of molecular glue degraders that bind cereblon and induce the degradation of proteins central to myeloma cell survival, including Ikaros and Aiolos. This combination rapidly reduced disease burden and allowed the team to proceed with a second BCMA-directed CAR T-cell infusion, this time using ciltacabtagene autoleucel, a product distinguished by a multi-targeting CAR design intended to enhance antigen recognition and reduce tumor escape.

Early post-infusion assessment showed a swift and profound response. Marked declines in serum IgA and free kappa light chains, key myeloma biomarkers, were observed, accompanied by robust expansion of the infused CAR T-cells in the patient’s circulation. The rapidity and depth of the response are particularly notable given the extensive prior treatment and the fact that the patient had already received one BCMA-directed product. The case demonstrates that preserved BCMA expression, confirmed molecularly before retreatment, may help identify patients likely to respond to a second BCMA-targeted cellular therapy.

treatment-related toxicities were described as manageable. The patient experienced grade II cytokine release syndrome, a common inflammatory side effect of CAR T-cell therapy mediated by immune signaling molecules released during T-cell activation, as well as prolonged cytopenias, a reduction in blood cell counts that persisted beyond the expected window. Importantly, there was no evidence of neurotoxicity, another recognized risk of CAR T-cell therapy. These findings reinforce the notion that carefully monitored retreatment can be delivered with an acceptable safety profile even in a heavily pretreated patient.

The authors emphasize that this single case provides additional knowledge rather than definitive proof. It suggests that retreatment with BCMA-directed CAR T-cell therapy may be feasible and clinically effective in heavily pretreated multiple myeloma, particularly in patients who achieved a durable response to their initial CAR T-cell infusion. The combination of bridging therapy to reduce tumor burden and the use of an alternative CAR T-cell construct may further improve outcomes by minimizing disease progression during manufacturing and by presenting the tumor with a different engineered receptor.

The report also highlights the growing role of genomic characterization in treatment planning. In this case, prior whole genome sequencing confirmed preserved BCMA expression, giving clinicians the confidence to pursue a second BCMA-directed approach rather than switching to an alternative target. As sequencing becomes more widely available, such molecular assessments may become a standard part of the decision-making process for patients considering CAR T-cell re-treatment.

Prospective studies will be needed to define optimal patient selection and treatment sequencing in this setting, the authors conclude. Key questions include which patients are most likely to benefit from a second BCMA-directed infusion, the ideal choice and duration of bridging therapy, and whether alternative CAR constructs truly outperform reinfusion of the original product. For now, this case adds to a small but growing body of evidence that a second CAR T-cell chance may be possible for some patients with advanced multiple myeloma.

Subject of Research: Retreatment with BCMA-directed CAR T-cell therapy after CELMoD-based bridging in relapsed multiple myeloma

Article Title: Early deep response to cilta-cel as 2nd CAR T-Cell therapy after CELMoD-based bridging for advanced multiple myeloma

Article References: Niklas, H., Bold, A., Völkl, S., Lang, N., Truger, M., Wendelin, K., Strifler, S., Gärtner, J., & Knop, S. (2026). Early deep response to cilta-cel as 2nd CAR T-Cell therapy after CELMoD-based bridging for advanced multiple myeloma. Annals of Hematology. https://doi.org/10.1007/s00277-026-07278-5

Image Credits: AI Generated

DOI: 10.1007/s00277-026-07278-5

Keywords: multiple myeloma, CAR T-cell therapy, BCMA, ciltacabtagene autoleucel, idecabtagene vicleucel, mezigdomide, CELMoD, bridging therapy, relapsed refractory myeloma, cytokine release syndrome, immunotherapy, cell therapy

Tarlatamab is a bispecific T-cell engager, a class of engineered antibody molecules designed to bring immune cells and tumor cells into close contact so that the immune system can attack the cancer directly. The drug binds DLL3, a protein abundantly expressed on the surface of small cell lung cancer cells but largely absent from healthy tissues, on one side, and CD3 on T cells on the other. By bridging these two cell types, tarlatamab activates the patient’s own T cells against the tumor. The therapy has already demonstrated established clinical activity in small cell lung cancer when administered intravenously, and an approved intravenous regimen of 10 milligrams every two weeks is in clinical use. What has been missing until now is evidence that the drug can be delivered in a simpler way without sacrificing efficacy or safety.

DeLLphi-308 is the first study to evaluate subcutaneous administration of tarlatamab, and the rationale for exploring this route goes well beyond convenience. Intravenous infusions deliver the full dose into the bloodstream rapidly, producing high peak serum concentrations shortly after administration. Subcutaneous injection, by contrast, allows the drug to be absorbed gradually from the injection site, producing lower peak concentrations that appear over a delayed timeframe. For a bispecific T-cell engager, this pharmacokinetic difference matters. Rapid peaks are thought to contribute to cytokine release syndrome, a systemic inflammatory reaction that is the most characteristic toxicity of this drug class and a frequent reason for hospitalization and intensive monitoring. If subcutaneous dosing flattens the concentration curve, it could potentially reduce the incidence or severity of cytokine release syndrome while delivering the same total drug exposure.

The open-label, multicenter study enrolled patients with extensive-stage small cell lung cancer whose disease had progressed or recurred after at least one platinum-based therapy, the standard first-line backbone for this disease. In the first part of the study, investigators compared subcutaneous target doses of 10 milligrams and 15 milligrams, each administered every two weeks. Pharmacokinetic analysis showed that the 15 milligram subcutaneous dose achieved serum exposures comparable to the established intravenous regimen of 10 milligrams every two weeks. On the strength of that matching exposure, the 15 milligram dose was selected as the target dose for the second part of the study, where safety and preliminary antitumor activity were assessed in a larger group of patients.

As of the March 5, 2026 data cutoff, 40 patients had received the 15 milligram subcutaneous target dose. Treatment-related adverse events occurred in 85 percent of these patients, with 10 percent experiencing a grade 3 or higher event, a rate that investigators characterized as consistent with a manageable safety profile. The most common treatment-related toxicities were injection-site reactions, seen in half of the patients, and dysgeusia, a distortion of taste reported by 45 percent. Cytokine release syndrome occurred in 38 percent of patients, and decreased appetite in 20 percent. No grade 5, or fatal, treatment-related adverse events were recorded, an important benchmark for a therapy that mobilizes the immune system against cancer.

The pattern of cytokine release syndrome observed in the study was particularly notable. Events were predominantly grade 1, the mildest category, and no patient experienced grade 3 or higher cytokine release syndrome. Equally significant, no cytokine release event required dose interruption or discontinuation of therapy. For a drug class in which cytokine release has historically dictated step-up dosing schedules, hospitalization and careful monitoring, the ability to deliver full therapeutic doses subcutaneously with predominantly mild inflammatory events represents a meaningful advance in tolerability. The investigators attribute this favorable profile at least in part to the lower, delayed peak serum concentrations achieved with subcutaneous absorption.

Early efficacy signals were also encouraging. The preliminary objective response rate in the 15 milligram group was 30 percent, meaning roughly one in three patients with previously treated extensive-stage small cell lung cancer experienced measurable tumor shrinkage. In a disease where outcomes after platinum failure have historically been poor and where effective options remain scarce, this level of activity from a more convenient route of administration is a noteworthy finding. The investigators concluded that subcutaneous tarlatamab was well tolerated and that the observed safety profile, pharmacokinetic findings and preliminary antitumor activity, together with the potential convenience of subcutaneous administration, support further investigation of this approach.

The clinical implications extend beyond the numbers. Intravenous administration of bispecific therapies typically requires infusion suites, extended clinic visits and, in many protocols, initial hospitalization to manage the risk of cytokine release during the first doses. A subcutaneous formulation that can be injected quickly, with a safety profile dominated by low-grade events, could eventually allow treatment closer to home, reduce the logistical burden on patients who often travel long distances to specialized cancer centers, and expand access to an effective immunotherapy for populations currently underserved. For patients with extensive-stage small cell lung cancer, who frequently face limited life expectancy and heavy symptom burden, every reduction in treatment inconvenience carries real weight.

Speaking about the findings, Pedro Rocha, MD, of Hospital Universitari Vall d’Hebron in Barcelona, Spain, and primary author of the study, emphasized the pharmacokinetic achievement at the heart of the results. The findings from DeLLphi-308 suggest that a 15 milligram subcutaneous tarlatamab dose can achieve serum exposures comparable to the approved 10 milligram intravenous dosing administered every two weeks while maintaining a favorable safety profile, he noted. The predominantly low-grade cytokine release events and the preliminary antitumor activity, he added, support continued investigation of this more convenient route of administration. Updated data from the latest data cutoff were scheduled to be shared in an oral presentation at the conference on September 15, offering a fuller picture of both durability of response and long-term tolerability.

The DeLLphi-308 results arrive at a moment of rapid evolution in the treatment of small cell lung cancer, a disease long defined by its aggressiveness and its tendency to relapse after initial response to chemotherapy. Bispecific T-cell engagers targeting DLL3 have emerged as one of the most promising strategies for the previously treated setting, and the present study addresses the practical question of how such therapies can best be delivered. While the findings remain preliminary, based on 40 patients at a single data cutoff, the combination of matched drug exposure, predominantly mild cytokine release syndrome, no fatal treatment-related events and a 30 percent response rate provides a solid foundation for the next phase of development. If larger studies confirm these results, subcutaneous tarlatamab could become a template for how potent immune-engaging cancer therapies are administered, pairing the biological power of bispecific antibodies with the simplicity of an injection rather than an infusion.

Subject of Research: Subcutaneous administration of the bispecific T-cell engager tarlatamab in previously treated extensive-stage small cell lung cancer

Article Title: Subcutaneous tarlatamab shows favorable safety profile and antitumor activity in extensive-stage small cell lung cancer

Article References: Subcutaneous tarlatamab shows favorable safety profile and antitumor activity in extensive-stage small cell lung cancer. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: tarlatamab, small cell lung cancer, DeLLphi-308, bispecific T-cell engager, subcutaneous immunotherapy, cytokine release syndrome, DLL3, IASLC, WCLC 2026, pharmacokinetics, extensive-stage SCLC, cancer immunotherapy

Tarlatamab is a bispecific T-cell engager, a designed molecule that simultaneously binds DLL3, a protein abundant on small cell lung cancer cells, and CD3 on T cells, physically drawing immune effector cells into contact with tumor cells and triggering cancer cell killing. When administered at 10 mg every two weeks, the drug has previously demonstrated superior overall survival compared with chemotherapy in patients whose disease had progressed after first-line treatment, a milestone that reshaped expectations for this notoriously aggressive malignancy. The central question of DeLLphi-309 was whether less frequent administration, at higher individual doses, could deliver comparable outcomes while easing the burden of frequent clinic visits.

In the trial, adults whose small cell lung cancer had progressed or recurred after first-line platinum-based chemotherapy were randomized to one of three intravenous regimens: 10 mg every two weeks, 20 mg every three weeks, or 30 mg every four weeks, each following a 1 mg step dose designed to mitigate initial immune-related toxicity. The primary endpoint was confirmed objective response rate as assessed by blinded independent central review. No formal statistical hypotheses were prespecified, and the findings were presented descriptively, meaning the results should be interpreted as exploratory rather than definitive comparative evidence.

As of May 7, 2026, 252 patients had been randomized across the three arms. Blinded independent central review confirmed objective response rates of 40% in the every-two-week group, 31% in the every-three-week group, and 27% in the every-four-week group. Investigator-assessed response rates told a somewhat more compressed story, at 36%, 37%, and 31%, respectively, highlighting how assessment methodology can influence the apparent magnitude of differences between schedules. Median progression-free survival by blinded independent central review was 4.2 months with the established every-two-week regimen, 4.1 months with the every-three-week schedule, and 2.7 months with the every-four-week schedule.

Overall survival data, while immature, added further nuance to the picture. Six-month overall survival rates were 72% with the every-two-week regimen, 85% with the every-three-week regimen, and 69% with the every-four-week regimen. Median overall survival had not yet been reached or estimated after approximately nine months of median follow-up across the three regimens, leaving the most consequential endpoint of all still open to maturation. The apparent survival advantage in the every-three-week arm, in particular, will require longer observation before any conclusions can be drawn.

Safety findings were broadly reassuring. Treatment-emergent and treatment-related adverse event rates were similar across the three dosing regimens, and investigators identified no new or unexpected safety signals. Cytokine release syndrome, the flu-like immune activation event characteristic of T-cell engagers, occurred in 60% to 70% of patients across arms but was predominantly grade 1 or 2 in severity. Immune effector cell-associated neurotoxicity syndrome, a rarer neurological toxicity, was observed in 6% to 12% of patients. Both events were numerically somewhat more frequent in the extended-interval arms, a pattern the researchers noted but did not attribute to a clear mechanism.

Pharmacokinetic analyses offered a mechanistic explanation for why the extended schedules worked as well as they did. Steady-state trough concentrations of tarlatamab were comparable across the three dosing schedules, indicating that increasing the individual dose from 10 mg to 20 mg or 30 mg successfully compensated for the longer gap between administrations. This dose-interval symmetry reflects the drug’s pharmacokinetic behavior, in which total drug exposure over time, rather than the frequency of administration per se, appears to drive both efficacy and tolerability.

Jonathan Goldman, M.D., of the University of California Los Angeles, who presented the findings, emphasized the practical implications. The data suggest that the 20 mg every-three-week and 30 mg every-four-week regimens may offer treatment flexibility for patients with small cell lung cancer, and that alternative dosing schedules for bispecific T-cell engagers generally may achieve outcomes consistent with an established regimen. For patients, fewer clinic visits can translate into less travel, reduced time away from home, and a treatment rhythm that is easier to sustain over months of therapy.

Small cell lung cancer accounts for roughly 10 to 15 percent of lung cancers and is characterized by rapid growth and early dissemination. Although initial platinum-based chemotherapy is often effective, relapse is nearly universal, and options in the second-line setting have historically delivered modest benefit. The arrival of tarlatamab marked the first meaningful expansion of the treatment arsenal in decades, and refining how the drug is delivered could extend its reach to patients for whom biweekly dosing is impractical.

The DeLLphi-309 results arrive amid a broader reassessment of how novel immunotherapies are scheduled. As experience with bispecific antibodies accumulates across hematologic and solid malignancies, investigators are increasingly testing whether dose intensity can be traded for convenience without sacrificing efficacy. For tarlatamab, the descriptive nature of these findings means longer follow-up and additional study will be needed to confirm whether extended-interval dosing can formally match the established every-two-week standard, but for a patient population with few options and significant treatment burdens, the prospect of a three- or four-week schedule represents a meaningful step toward more humane cancer care.

Subject of Research: Extended-interval tarlatamab dosing in previously treated small cell lung cancer evaluated in the Phase 2 DeLLphi-309 trial

Article Title: Extended-interval tarlatamab dosing shows consistent activity and safety in previously treated small cell lung cancer

Article References: Extended-interval tarlatamab dosing shows consistent activity and safety in previously treated small cell lung cancer. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: tarlatamab, small cell lung cancer, DeLLphi-309, bispecific T-cell engager, DLL3, cytokine release syndrome, ICANS, dosing schedule, IASLC, WCLC 2026, immunotherapy, progression-free survival